Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

Oncology has entered a new era with the approval of anti-cancer drugs that harness the immune system of a patient to fight back against cancer. The tumor microenvironment approach of NOXXON to disrupting the cancer’s ability to escape the attack of the immune system is unique in the biopharmaceutical industry as it directly blocks the ability of the tumor to exploit the molecular signposts in the body used by cells on the move. The therapeutic goal is to remove the barriers or “detour” signs that cancers build to keep the immune system away.

NOXXON is intensely focused on advancing its innovative therapeutic candidates through clinical development to demonstrate their potential to improve outcomes for cancer patients. Our compounds are designed to enhance the efficacy of both novel immuno-oncology approaches, such as immune checkpoint inhibitors, and current standards of care, such as chemotherapy and radiotherapy. The proprietary product candidates, discovered and developed by NOXXON, based on our unique (Spiegelmer*) drug discovery platform, are centered on targeting the tumor microenvironment and disrupting the signaling used by cancer cells to deflect the immune system detection and attack.

Our lead candidate, NOX-A12, is in development as a combination therapy for multiple cancer indications where its impact on the tumor microenvironment is intended to significantly enhance the effectiveness of anti-cancer treatments without adding significant side effects for patients. NOX-A12 has delivered promising top-line data in a Phase 1/2 trial in metastatic pancreatic and colorectal cancer patients who are not expected to respond to checkpoint inhibition alone. NOX-A12 has also completed two Phase 2a trials, one in chronic lymphocytic leukemia and the other in in multiple myeloma. Read more here.

Our second clinical-stage oncology candidate, NOX-E36, is able to target multiple tumor microenvironment chemokines that appear to be relevant to tumor evasion of the immune system. NOX-E36 has completed exploratory clinical studies in additional indications, establishing its activity on the biological targets and its safety profile, but we are now focused in its application in oncology where preclinical data has shown activity in models of solid tumors like pancreas and liver cancer. Read more here.


Pipline NOXXON

* Subject to additional financing
1. Feig, C. et al. PNAS 110.50 (2013): 20212-20217; Fearon, D. Cancer Immunol Research 2.187 (2014): 187-193; Poznansky, M., Nature America 6:543 (2000): 543-548; Zboralski, D. et al. Cancer Immunol Research (2017) 5(11); 950–6
2. Liu, S. et al. Neuro-Oncology 16.1 (2013): 1-8; Castro, B. & Aghi, M. Neuro-Oncology 16.1 (2014): 4-6
3. Nywening Lancet Oncol 2016 http://dx.doi.org/10.1016/S1470-2045(16)00078-4; J. Lazarus et al. (2017) Poster PT165. Society of Surgical Oncology 70th Annual Cancer Symposium; Bartneck et al. Cell Mol Gastroenterol Hepatol, (2019) 7:371–390